RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed...
The article Which Psychedelic Medicine Companies Have the Best Financials? was originally published on Microdose. As I have written many times before,...
The first three months of 2023 have been a whirlwind for the psychedelic industry– to say the least. Though it has been a particularly difficult quarter,...
The article News You Might Have Missed: May 1st, 2023 was originally published on Microdose. Welcome to the News You Might Have Missed, a weekly roundup...
Truffle Report has compiled a roundup of major psychedelic business news stories from the week of February 7-11, making it easier for you to access these...
The article News You Might Have Missed: April 24th, 2023 was originally published on Microdose. Welcome to the News You Might Have Missed, a weekly roundup...
The article Atai Partner IntelGenx Announces FDA Approval of Oral Film was originally published on Microdose. Under-the-radar firm IntelGenx has just...
The article News You Might Have Missed: April 17th, 2023 was originally published on Microdose. Welcome to the News You Might Have Missed, a weekly roundup...
The article Atai Starts New Phase 1 Study of PCN-101 (R-Ketamine) was originally published on Microdose. Back in January, atai Life Sciences released...
Psychedelic Invest’s parent company, Nucleus Holding, Inc. is slated to close its crowdfunding campaign this month. Over on the campaign page at Wefunder,...